Core Viewpoint - Calidi Biotherapeutics is making significant progress in advancing its lead asset CLD-401 towards clinical trials, with a focus on innovative approaches in cancer treatment and strategic partnerships to enhance its development pipeline [2][4]. Fourth Quarter 2025 Financial Results - The company reported a net loss of $4.1 million, or $0.57 per share, for Q4 2025, which is an improvement from a net loss of $4.1 million, or $3.23 per share, in Q4 2024 [3]. - Research and development expenses increased to $2.4 million in Q4 2025 from $1.8 million in Q4 2024 [6]. - General and administrative expenses slightly decreased to $2.1 million in Q4 2025 from $2.2 million in Q4 2024 [6]. Full Year 2025 Financial Results - For the full year 2025, the company reported a net loss of $25.6 million, or $5.95 per share, compared to a net loss of $23.8 million, or $35.70 per share, in 2024 [7]. - Research and development expenses for the year were $9.7 million, up from $8.9 million in 2024 [7]. - General and administrative expenses decreased to $10.5 million in 2025 from $12.9 million in 2024 [8]. Cash Position - As of December 31, 2025, the company had approximately $5.6 million in cash, down from $9.6 million as of December 31, 2024 [8]. Strategic Partnerships and Developments - Calidi has partnered with Avance Clinical to expedite the initiation of the CLD-401 clinical trial in Australia, leveraging their expertise in regulatory approval [4][5]. - The company is also collaborating with Matica Bio for GMP manufacturing of CLD-401, which is designed to target tumor cells specifically [5]. - Calidi presented new data on in situ T-cell engagers at the 2026 AACR-IO conference, showcasing advancements in their therapeutic approach [4][5]. Pipeline and Product Focus - CLD-401, the lead candidate from the RedTail platform, is currently in IND-enabling studies and targets various cancers with high unmet medical needs [10]. - The RedTail platform aims to deliver genetic medicines effectively to metastatic sites while minimizing peripheral exposure [9].

Core Insights - Calidi Biotherapeutics has announced a partnership with Avance Clinical to initiate a first-in-human clinical trial for its lead candidate CLD-401 in Australia, while also pursuing an IND filing with the FDA in 2026 [1][3]. Company Overview - Calidi Biotherapeutics is a biotechnology company focused on developing targeted therapies that deliver genetic medicines to distal disease sites, utilizing its proprietary RedTail platform [4][5]. - The RedTail platform features an engineered enveloped oncolytic virus designed for systemic delivery and targeting of metastatic sites, aiming to shield the virus from immune clearance [4]. Product Details - CLD-401 is a genetically modified vaccinia virus that replicates only in tumor cells and expresses high levels of IL-15 superagonist, which activates both innate and adaptive immune responses in the tumor microenvironment [2]. - The planned Phase I trial will assess the safety, pharmacodynamics, and efficacy of CLD-401 as a monotherapy for patients with solid tumors that have no other therapeutic options available [2]. Strategic Goals - The company aims to expedite clinical studies for CLD-401 to provide a potential treatment option for patients resistant to current therapies [3]. - Calidi is actively pursuing strategic partnerships to enhance clinical development and broaden the impact of its RedTail platform [3].

Core Viewpoint - Calidi Biotherapeutics is advancing its proprietary RedTail platform and its lead candidate CLD-401, which targets metastatic tumors and aims to enhance the delivery of genetic medicines [1][6]. Group 1: Company Overview - Calidi Biotherapeutics is a biotechnology company focused on developing targeted therapies for delivering genetic medicines to distal sites of disease [6]. - The RedTail platform utilizes an engineered enveloped oncolytic virus designed for systemic delivery and targeting of metastatic sites, shielding the virus from immune clearance [6]. Group 2: Product Development - CLD-401 is the first lead candidate from the RedTail platform, currently in IND-enabling studies, targeting non-small cell lung cancer, head and neck cancer, and other tumor types with high unmet medical need [7]. - The company anticipates submitting an Investigational New Drug (IND) application for CLD-401 by the end of 2026 [5]. Group 3: Manufacturing and FDA Interaction - Calidi presented its proprietary manufacturing process for CLD-401 at the BioProcessing Summit, emphasizing its scalability and high-yield capabilities [3]. - The manufacturing process maintains the integrity of the CD55 over-expressing envelope, which is crucial for systemic delivery and preventing immune recognition [3]. - Feedback from the FDA supports the company's manufacturing and analytical approaches, indicating a positive outlook for clinical development [4][5]. Group 4: Strategic Partnerships and Future Plans - The company is actively pursuing strategic partnerships to accelerate clinical development and broaden the impact of its RedTail platform [5]. - Calidi continues to expand the functionality of the RedTail platform, including incorporating T-cell engagers in solid tumors [7].

Core Viewpoint - Calidi Biotherapeutics, Inc. has successfully closed a public offering, raising approximately $6.0 million in gross proceeds, which will support its ongoing development of targeted genetic medicines [1][2]. Group 1: Offering Details - The company sold a total of 12,094,631 shares of common stock and associated warrants, including the full exercise of the underwriters' option for an additional 1,575,000 shares [2]. - The Series J, K, and L warrants each have an initial exercise price of $0.50 per share, with varying terms of five years, one year, and six months from issuance respectively [5]. Group 2: Company Overview - Calidi Biotherapeutics is focused on developing targeted therapies that deliver genetic medicines to specific disease sites, utilizing its proprietary Redtail platform [7]. - The lead candidate, CLD-401, is currently in IND-enabling studies and targets non-small cell lung cancer and other high unmet medical need tumor types [8].

Core Viewpoint - Calidi Biotherapeutics, Inc. has announced a public offering of 10,519,631 units, aiming to raise approximately $5.2 million for working capital and general corporate purposes [3][5]. Offering Details - Each unit consists of one share of common stock (or a pre-funded warrant), along with three types of warrants: a 6-month warrant, a 12-month warrant, and a 5-year warrant [1][6]. - The offering price is set at $0.50 per unit, with pre-funded units priced at the public offering price minus a nominal exercise price of $0.001 per share [3][6]. - The underwriter, Ladenburg Thalmann & Co. Inc., has a 45-day option to purchase up to an additional 1,575,000 shares or warrants to cover over-allotments [4]. Financial Implications - The gross proceeds from the offering are expected to be approximately $5.2 million before deducting underwriting discounts and commissions [3]. - The company has also agreed to amend existing warrants held by investors to reduce the exercise price to $0.50 per share upon closing of the offering [7]. Company Overview - Calidi Biotherapeutics is focused on developing targeted genetic medicines, utilizing its proprietary Redtail platform, which features an engineered enveloped oncolytic virus for systemic delivery to metastatic sites [10][11]. - The lead candidate, CLD-401, is currently in IND-enabling studies and targets non-small cell lung cancer and other high unmet medical need tumor types [11].

Core Insights - Calidi Biotherapeutics is presenting data on its innovative RedTail platform for targeted genetic medicines at the AACR Immuno-Oncology conference, focusing on its application in solid tumors [1][3] Group 1: RedTail Platform - The RedTail platform is designed for systemic delivery of virotherapy, targeting tumors and remodeling the tumor microenvironment (TME) to enhance therapeutic efficacy [2][5] - CLD-401, the lead candidate from the RedTail platform, is engineered to express high levels of IL-15 superagonist (IL-15 SA), which activates T-cells within the TME [2][6] Group 2: Clinical Development - Data presented indicates that RedTail can express both a functional BiTE and IL-15 SA, facilitating T-cell activation and TME alteration simultaneously, potentially overcoming previous limitations of BiTEs in solid tumors [3][4] - Calidi is conducting IND-enabling studies for CLD-401, targeting non-small cell lung cancer, head and neck cancer, and other high unmet medical need tumor types, with plans to submit an Investigational New Drug (IND) application by the end of 2026 [4][6] Group 3: Company Overview - Calidi Biotherapeutics is focused on developing targeted therapies that deliver genetic medicines to metastatic disease sites, utilizing an engineered enveloped oncolytic virus to shield from immune clearance [5][6] - The company is actively pursuing strategic partnerships to enhance clinical development and expand the impact of its RedTail platform [4]

Core Insights - Calidi Biotherapeutics is set to present data on its innovative use of BiTEs in solid tumors through its RedTail platform at the AACR Immuno-Oncology conference from February 18-21, 2026 [1] Company Overview - Calidi Biotherapeutics is a biotechnology company focused on developing targeted genetic medicines, utilizing its proprietary RedTail platform for systemic delivery to metastatic sites [5] - The RedTail platform employs an engineered enveloped oncolytic virus designed to evade immune clearance, allowing effective delivery of genetic medicines to tumor sites [5] Product Development - The lead candidate from the RedTail platform, CLD-401, is engineered to express high levels of IL-15 superagonist, which activates T-cells within the tumor microenvironment [2][3] - CLD-401 is currently in IND-enabling studies and targets non-small cell lung cancer, head and neck cancer, and other tumor types with significant unmet medical needs [6] - The company plans to submit an Investigational New Drug (IND) application for CLD-401 by the end of 2026 [4] Technological Advancements - The RedTail platform has shown the ability to remodel the tumor microenvironment and induce T-cell activation, which is crucial for overcoming the limitations of BiTEs in solid tumors [3] - The platform allows for the simultaneous expression of multiple tumor-localized payloads, enhancing the potential for effective treatment [3] Strategic Initiatives - Calidi is actively pursuing strategic partnerships to accelerate the clinical development of its RedTail platform and broaden its impact in the biotechnology sector [4]